Industry: Pharmaceuticals, Biotechnology
CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company’s lead product candidate, Canvaxin(TM), is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines. Canvaxin(TM) is currently being studied in two international Phase 3 clinical trials for the treatment of patients with Stage III or Stage IV, or advanced-stage, melanoma. CancerVax anticipates that enrollment in the Phase 3 clinical trial of Canvaxin(TM) for patients with Stage III melanoma will be completed in ( www.cancervax.com )
CancerVax Corporation
2110 Rutherford Road
Carlsbad, California 92008
USA
Tel: (760) 494-4200
Fax: (760) 431-9980